Steve Harvey/LinkedIn
Sep 19, 2025, 06:06
Aspirin as Precision Medicine? Steve Harvey Highlights Evidence for PIK3-Mutated Colorectal Cancer Patients
Steve Harvey, CEO of Camena Bioscience, shared a post on LinkedIn:
“A very interesting study indicates that Aspirin could be a precision medicine for colorectal cancer.
The study, which was publicised in the New England Journal of Medicine, studied 3500 patients with colorectal cancer.
~40% of those patients had mutations in genes associated with the PIK3 signalling pathway.
Those patients with the PIK3 associated mutations and taking aspirin, were 55% less likely to have the cancer return than those on placebo.
P.s. I’ll add the Guardian article to the comments.”
You can read the full article here.
More posts featured in Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia